Literature DB >> 29052861

Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.

C Gouynou1, L Peyrin-Biroulet1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29052861     DOI： 10.1111/apt.14320

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  6 in total

Review 1.  Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.

Authors:  Lieven Pouillon; Séverine Vermeire; Peter Bossuyt
Journal:  BMC Med       Date:  2019-05-08       Impact factor: 8.775

2.  Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.

Authors:  Wan-Ting Cao; Rong Huang; Ke-Fang Jiang; Xue-Hui Qiao; Jing-Jing Wang; Yi-Hong Fan; Yi Xu
Journal:  World J Gastroenterol       Date:  2021-03-07       Impact factor: 5.742

Review 3.  Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications.

Authors:  Andrea Cassinotti; Alberto Batticciotto; Marco Parravicini; Maurizio Lombardo; Paolo Radice; Claudio Camillo Cortelezzi; Simone Segato; Federico Zanzi; Antonella Cappelli; Sergio Segato
Journal:  Therap Adv Gastroenterol       Date:  2022-03-23       Impact factor: 4.409

4.  Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis.

Authors:  Makoto Naganuma; Kenji Watanabe; Satoshi Motoya; Haruhiko Ogata; Toshiyuki Matsui; Yasuo Suzuki; Lyann Ursos; Shigeru Sakamoto; Mitsuhiro Shikamura; Tetsuharu Hori; Jovelle Fernandez; Mamoru Watanabe; Toshifumi Hibi; Takanori Kanai
Journal:  J Gastroenterol Hepatol       Date:  2021-09-07       Impact factor: 4.369

Review 5.  Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.

Authors:  Maria Lia Scribano
Journal:  World J Gastroenterol       Date:  2018-06-21       Impact factor: 5.742

6.  Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease.

Authors:  Timothy Wyant; Lili Yang; Richard A Lirio; Maria Rosario
Journal:  J Clin Pharmacol       Date:  2021-07-14       Impact factor: 3.126
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.